Angiogenic Switch in Patients With Colorectal Cancer
Status:
Unknown status
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev)
maintain the same sensitivity after progression to maintenance treatment because they remain
dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic
switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev
chemotherapy combinations .